International management platform for children's interstitial lung disease (chILD-EU).
Matthias Griese, Elias Seidl, Meike Hengst...
https://pubmed.ncbi.nlm.nih.gov/29056600Actively Recruiting
Led by Matthias Griese · Updated on 2022-09-21
1000
Participants Needed
3
Research Sites
52 weeks
Total Duration
This research aims to create a common European database and biobank focused on childhood interstitial lung diseases (chILD). It seeks to continuously assess and apply guidelines and treatment protocols, establish a large observational cohort of chILD patients, and evaluate the value of various clinical outcomes. The study also aims to assess treatment variations and provide data to support future clinical trial protocols. The project will adapt existing national data collection programs from France, Germany, and the UK into a pan-European web-based database and biobank compatible with similar efforts in the United States. Regular meetings of an expert Standards Working Group will establish diagnostic pathways, including protocols for clinical data gathering, blood tests, imaging, and pathology. An international panel will review diagnoses for quality control, and follow-up protocols will generate natural history data. Recruitment will be Europe-wide, with independent review of diagnoses and ongoing monitoring of local clinical decisions and outcomes. Participants will be part of a carefully characterized chILD cohort, with clinical, imaging, lung function, histopathology, serum markers, and genetic data collected and assessed. The study will investigate reproducibility and variability of data, including training effects on image reading. Treatment practices and outcomes will be analyzed across subjects to inform future trials. The primary outcome measure is the number of subjects with specific diagnoses over ten years, with survival also tracked for the same period.
CONDITIONS
European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank
You may qualify if you...
You will not qualify if you...
Complete this quick 3-step screening to check your eligibility
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Variable, ongoing as new information becomes available
Participants undergo detailed diagnostic assessments including clinical information gathering, blood testing, imaging, and pathology to establish or review diagnosis.
Duration - Up to 10 years
Participants are followed over time to collect natural history data, treatment variations, and outcomes related to childhood interstitial lung diseases.
Total: 3 locations
1
Medizinische Hochschule Hannover
Hanover, Lower Saxony, Germany, 30625
Actively Recruiting
2
Hacettepe University, Medical Faculty
Ankara, Sihhiye, Turkey (Türkiye), 06100
Actively Recruiting
3
University of Edinburgh
Edinburgh, United Kingdom, EH4 2XU
Actively Recruiting
M
Matthias Griese, Prof.
K
Katarzyna Michel, Dr. med.
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Have more questions? Get in touch with our team for quick support
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Matthias Griese, Elias Seidl, Meike Hengst...
https://pubmed.ncbi.nlm.nih.gov/29056600